IGF-2 has been observed to be activated and expressed inappropriately in several malignancies, including but not limited to hepatocellular carcinoma, colon cancer, liposarcoma, and embryonic tumors [35–38]. This evidence concerns the gene IGF2 and hepatocellular carcinoma.